Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Iron overload is the hallmark of hereditary hemochromatosis and a complication of iron-loading anemias such as β-thalassemia. Treatment can be burdensome and have significant side effects, and new therapeutic options are needed. Iron overload in hereditary hemochromatosis and β-thalassemia intermedia is caused by hepcidin deficiency. Although transgenic hepcidin replacement in mouse models of these diseases prevents iron overload or decreases its potential toxicity, natural hepcidin is prohibitively expensive for human application and has unfavorable pharmacologic properties. Here, we report the rational design of hepcidin agonists based on the mutagenesis of hepcidin and the hepcidin-binding region of ferroportin and computer modeling of their docking. We identified specific hydrophobic/aromatic residues required for hepcidin-ferroportin binding and obtained evidence in vitro that a thiol-disulfide interaction between ferroportin C326 and the hepcidin disulfide cage may stabilize binding. Guided by this model, we showed that 7–9 N-terminal amino acids of hepcidin, including a single thiol cysteine, comprised the minimal structure that retained hepcidin activity, as shown by the induction of ferroportin degradation in reporter cells. Further modifications to increase resistance to proteolysis and oral bioavailability yielded minihepcidins that, after parenteral or oral administration to mice, lowered serum iron levels comparably to those after parenteral native hepcidin. Moreover, liver iron concentrations were lower in mice chronically treated with minihepcidins than those in mice treated with solvent alone. Minihepcidins may be useful for the treatment of iron overload disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Minihepcidins are synthetic hepcidin agonists previously shown to bind ferroportin and induce its endocytosis and proteolysis, thus preventing iron overload in hepcidin-deficient mice (Preza et al., 2011; Ramos et al., 2012).”
From Hepcidin-Induced Hypoferremia Is a Critical Host Defense Mechanism against the Siderophilic Bacterium Vibrio vulnificus (2015) · cites this paper as Preza et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other interactions between FPN and hepcidin are either hydrophobic or depend on hepcidin amide backbone atoms, which is consistent with the relatively high tolerance of amino acid substitutions within hepcidin 40 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“This led to the development of mini-hepcidin analogs containing a minimal core of 7–9 N-terminal amino acids with a single cysteine, which suffice to trigger ferroportin internalization and degradation in cells and mice (Preza et al., 2011).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Preza et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: The Hepcidin-Binding Site on Ferroportin Is Evolutionarily Conserved
De Domenico, I., Nemeth, E., Nelson, J. M., Phillips, J. D., Ajioka, R. S., Kay, M. S., Kushner, J. P., Ganz, T., Ward, D. M., & Kaplan, J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.002 · Cited by 129
Self-citationRetractedHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Self-citationNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
Self-citationZDOCK: An initial‐stage protein‐docking algorithm
Chen, R., Li, L., & Weng, Z. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10389 · Cited by 1,393
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L. E., Franchini, P. L., Dubé, M.-P., Andres, L., MacFarlane, J., Sakellaropoulos, N., Politou, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1274 · Cited by 974 · cited 1×
“Discussion In hereditary hemochromatosis, hepcidin deficiency is a consequence of destructive mutations in the genes encoding hepcidin (24) or one of its regulators, HFE (3) (most common), transferrin receptor 2 (25), or hemojuvelin (26).”
BackgroundSelf-citationMutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis
Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., Loukopoulos, D., & Camaschella, C. (2003) · Nature Genetics · doi:10.1038/ng1053 · Cited by 860 · cited 1×
“Discussion In hereditary hemochromatosis, hepcidin deficiency is a consequence of destructive mutations in the genes encoding hepcidin (24) or one of its regulators, HFE (3) (most common), transferrin receptor 2 (25), or hemojuvelin (26).”
BackgroundSreerama, N., Venyaminov, S. Y. U., & Woody, R. W. (1999) · Protein Science · doi:10.1110/ps.8.2.370 · Cited by 708
Immunoassay for human serum hepcidin
Ganz, T., Olbina, G., Girelli, D., Nemeth, E., & Westerman, M. (2008) · Blood · doi:10.1182/blood-2008-02-139915 · Cited by 688
Self-citationThe RosettaDock server for local protein-protein docking
Lyskov, S., & Gray, J. J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn216 · Cited by 592
Suppression of hepcidin during anemia requires erythropoietic activity
Pak, M., Lopez, M. A., Gabayan, V., Ganz, T., & Rivera, S. (2006) · Blood · doi:10.1182/blood-2006-06-028787 · Cited by 472 · cited 1×
“Nonheme iron concentration was determined as described (44), using”
MethodSelf-citationHepcidin and disorders of iron metabolism
Ganz, T., & Nemeth, E. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050109-142444 · Cited by 466 · cited 1×
“Introduction Hepcidin is a peptide hormone that mediates systemic iron homeostasis in vertebrates (1).”
BackgroundSelf-citationPalmitoylation of Ligands, Receptors, and Intracellular Signaling Molecules
Resh, M. D. (2006) · Science's STKE · doi:10.1126/stke.3592006re14 · Cited by 414
Hepcidin is decreased in TFR2 hemochromatosis
Nemeth, E., Roetto, A., Garozzo, G., Ganz, T., & Camaschella, C. (2005) · Blood · doi:10.1182/blood-2004-08-3042 · Cited by 399
Self-citationPietrangelo, A. (2004) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2003.08.003 · Cited by 383
Liver iron concentrations and urinary hepcidin in -thalassemia
Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G., & Nemeth, E. (2007) · Haematologica · doi:10.3324/haematol.10842 · Cited by 365 · cited 3×
“In the absence of transfusions (β-thalassemia intermedia), hepcidin levels are very low (4, 5), and patients develop iron overload similar to that of severe hereditary hemochromatosis and may succumb to iron overload if untreated (29).”
BackgroundSelf-citationThalassemia intermedia: Revisited
Taher, A., Isma'eel, H., & Cappellini, M. D. (2006) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2006.04.005 · Cited by 319
Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis
Nicolas, G., Viatte, L., Lou, D.-Q., Bennoun, M., Beaumont, C., Kahn, A., Andrews, N. C., & Vaulont, S. (2003) · Nature Genetics · doi:10.1038/ng1150 · Cited by 311 · cited 1×
“The proof of this concept was achieved in mouse model of HFE hereditary hemochromatosis, in which the introduction of a hepcidin transgene into Hfe–/– mice prevented the development of iron overload (33).”
BackgroundNemeth, E., Preza, G. C., Jung, C.-L., Kaplan, J., Waring, A. J., & Ganz, T. (2006) · Blood · doi:10.1182/blood-2005-05-2049 · Cited by 273 · cited 5×
“Identification of hepcidin residues critical for binding to ferroportin We showed previously that deletion of the 5 N-terminal residues of hepcidin ablated the ability of the peptide to cause ferroportin degradation (16).”
BackgroundMethodInfluentialSelf-citationTargeted disruption of the hepcidin 1 gene results in severe hemochromatosis
Lesbordes-Brion, J.-C., Viatte, L., Bennoun, M., Lou, D.-Q., Ramey, G., Houbron, C., Hamard, G., Kahn, A., & Vaulont, S. (2006) · Blood · doi:10.1182/blood-2006-02-003376 · Cited by 257 · cited 2×
“out mice, originally provided to our laboratory by Sophie Vaulont (43).”
MethodEvidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice
Ramos, E., Kautz, L., Rodriguez, R., Hansen, M., Gabayan, V., Ginzburg, Y., Roth, M.-P., Nemeth, E., & Ganz, T. (2011) · Hepatology · doi:10.1002/hep.24178 · Cited by 238
Self-citationHepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice
Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., Muirhead, K., Rao, N., Roy, C. N., Andrews, N. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41717 · Cited by 220 · cited 1×
“Although the mechanism is still not understood, transgenic expression of hepcidin in a mouse model of β-thalassemia intermedia increased hemoglobin and decreased extramedullary erythropoiesis (37).”
BackgroundSelf-citationHepcidin Revisited, Disulfide Connectivity, Dynamics, and Structure
Jordan, J. B., Poppe, L., Haniu, M., Arvedson, T., Syed, R., Li, V., Kohno, H., Kim, H., Schnier, P. D., Harvey, T. S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.017764 · Cited by 214 · cited 2×
“Although we previously partially explored this question (16), the hepcidin structure has since been revised (18), and we generated synthetic hepcidin mutants in which we substituted pairs of cyste-”
Hepcidin Expression in the Liver: Relatively Low Level in Patients with Chronic Hepatitis C
Fujita, N., Sugimoto, R., Takeo, M., Urawa, N., Mifuji, R., Tanaka, H., Kobayashi, Y., Iwasa, M., Watanabe, S., Adachi, Y., et al. (2007) · Molecular Medicine · doi:10.2119/2006-00057.fujita · Cited by 211
Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia
Rivera, S., Liu, L., Nemeth, E., Gabayan, V., Sorensen, O. E., & Ganz, T. (2005) · Blood · doi:10.1182/blood-2004-08-3375 · Cited by 196 · cited 1×
“The half-life of natural hepcidin is very short (11) due to its rapid renal excretion.”
BackgroundSelf-citationUrinary hepcidin in congenital chronic anemias
Kearney, S. L., Nemeth, E., Neufeld, E. J., Thapa, D., Ganz, T., Weinstein, D. A., & Cunningham, M. J. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.20616 · Cited by 172 · cited 3×
“In the absence of transfusions (β-thalassemia intermedia), hepcidin levels are very low (4, 5), and patients develop iron overload similar to that of severe hereditary hemochromatosis and may succumb to iron overload if untreated (29).”
BackgroundSelf-citationReduced serum hepcidin levels in patients with chronic hepatitis C
Girelli, D., Pasino, M., Goodnough, J. B., Nemeth, E., Guido, M., Castagna, A., Busti, F., Campostrini, N., Martinelli, N., Vantini, I., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.06.027 · Cited by 169
Self-citationThe molecular basis of hepcidin-resistant hereditary hemochromatosis
Fernandes, A., Preza, G. C., Phung, Y., De Domenico, I., Kaplan, J., Ganz, T., & Nemeth, E. (2009) · Blood · doi:10.1182/blood-2008-03-146134 · Cited by 167
Self-citationFunctional consequences of ferroportin 1 mutations
Liu, X.-B., Yang, F., & Haile, D. J. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2005.04.005 · Cited by 156
Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis
Piperno, A., Girelli, D., Nemeth, E., Trombini, P., Bozzini, C., Poggiali, E., Phung, Y., Ganz, T., & Camaschella, C. (2007) · Blood · doi:10.1182/blood-2007-06-096503 · Cited by 152
Self-citationKim, S., Yazici, Y. D., Calzada, G., Wang, Z.-Y., Younes, M. N., Jasser, S. A., El-Naggar, A. K., & Myers, J. N. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0595 · Cited by 138
Iron in Nonhemochromatotic Liver Disorders
Alla, V., & Bonkovsky, H. L. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-923317 · Cited by 124
Rice, A. E., Mendez, M. J., Hokanson, C. A., Rees, D. C., & Björkman, P. J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.12.063 · Cited by 97
Fujita, N., Sugimoto, R., Motonishi, S., Tomosugi, N., Tanaka, H., Takeo, M., Iwasa, M., Kobayashi, Y., Hayashi, H., Kaito, M., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.05.014 · Cited by 89
Viatte, L. (2006) · Blood · doi:10.1182/blood-2005-10-4071 · Cited by 85
Wang, W., Mulakala, C., Ward, S. C., Jung, G., Luong, H. T., Pham, D. S. L., Waring, A. J., Kaznessis, Y. N., Lu, W., Bradley, K. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603614200 · Cited by 85
Self-citationWallace, D. F., Harris, J. M., & Subramaniam, V. N. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00621.2008 · Cited by 80
Sham, R. L., Phatak, P. D., Nemeth, E., & Ganz, T. (2009) · Blood · doi:10.1182/blood-2009-04-216226 · Cited by 74
Self-citationGualdi, R., Casalgrandi, G., Montosi, G., Ventura, E., & Pietrangelo, A. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90237-2 · Cited by 67
Optimizing iron chelation strategies in β-thalassaemia major
Porter, J. B. (2009) · Blood Reviews · doi:10.1016/s0268-960x(09)70003-7 · Cited by 67
Understanding the Structure/Activity Relationships of the Iron Regulatory Peptide Hepcidin
Clark, R. J., Tan, C. C., Preza, G. C., Nemeth, E., Ganz, T., & Craik, D. J. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.009 · Cited by 56
Self-citationScreening for Hemochromatosis: Recommendation Statement
U.S. Preventive Services Task Force* (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-3-200608010-00008 · Cited by 55
Chelation therapy for iron overload
Barton, J. C. (2007) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0024-9 · Cited by 51
Update on Thalassemia: Clinical Care and Complications
Cunningham, M. J. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2008.02.002 · Cited by 44
A tincture of hepcidin cures all: the potential for hepcidin therapeutics
Bartnikas, T. B., & Fleming, M. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci45043 · Cited by 16
2009 International BioIron Society Meeting
(2009) · American Journal of Hematology · doi:10.1002/ajh.21464 · Cited by 5
Cited by
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Self-citationGanz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
“Alanine scanning of this ferroportin loop identified additional residues critical for hepcidin binding (193).”
BackgroundInfluentialSelf-citationTaher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31822-6 · Cited by 807
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Metadata
- Authors
- Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E.
- Affiliations
- University of California, Los Angeles (US)
- Columbia University (US)
- California Institute of Technology (US)
- University of California, Irvine (US)
- Corresponding author
- Nemeth, Elizabeta
- Venue
- Journal of Clinical Investigation
- Published
- 2011-12-01
- Volume
- 121
- Issue
- 12
- Pages
- 4880-4888
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3225996
- OpenAlex
- W2146444665
- Cited by
- 234
- References
- 45
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 11 · 2023: 15 · 2022: 18 · 2021: 12 · 2020: 16 · 2019: 15 · 2018: 12 · 2017: 29 · 2016: 18 · 2015: 20 · 2014: 13 · 2013: 22 · 2012: 17
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Funders
- National Institutes of Health
- Center for AIDS Research, University of Washington
- University of California, Irvine
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065029, R01DK082717)
- Jonsson Comprehensive Cancer Center
- California NanoSystems Institute
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- iron overload, hereditary hemochromatosis, beta-thalassemia intermedia, ferroportin, oral bioavailability, serum iron, liver iron, peptide design
- MeSH terms
- Ferroportin, Amino Acid Sequence, Animals, Binding Sites, Computer Simulation, Cysteine, Drug Evaluation, Preclinical, Humans, Iron, Liver, Models, Molecular, Molecular Sequence Data, Peptide Fragments, Protein Conformation, Structure-Activity Relationship, Drug Design, Mutagenesis, Site-Directed, Iron Overload, Amino Acid Substitution, Antimicrobial Cationic Peptides, Protein Interaction Mapping, Cation Transport Proteins, Mice, Hydrophobic and Hydrophilic Interactions, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.